Olanzapine Pamoate Monohydrate
Recommended PsychiatryAuthority Required (Streamlined)Not applicable line
treatment of schizophrenia in adult patients who can be stabilised with oral olanzapine
1
Submissions
2009–09
On the record
—
ICER range
Cost-min
Cost basis
Decisions on record
- Meeting Jul 2013 Recommended Bipolar disorder no PSD
- Meeting Nov 2011 Recommended Schizophrenia no PSD
- Meeting Nov 2010 Recommended Anti-psychotic drug no PSD
- Meeting Mar 2010 Recommended Schizophrenia, bi-polar disorder no PSD
- Meeting Jul 2009 Recommended Schizophrenia
- Meeting Mar 2007 Recommended Antipsychotic drug no PSD
- Meeting Jul 2004 Recommended Treatment for schizophrenia and bipolar disorder no PSD
Access path
- Jul 2009Recommended · restricted
vs risperidone modified release injection
- PBS listing · Authority Required (Streamlined)
RecommendedDeferredNot recommended
Cost-effectiveness
Cost-minimisation analysis performed; no ICER calculated
Decision context
Populationadult patients who can be stabilised with oral olanzapine and are treated for schizophrenia
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Jul 2009 | Recommended · restricted | risperidone modified release injection | — | RCT | Single-arm · PANSS total score, exacerbation rates of schizophrenia |
Similar precedents
Regulatory · TGA
Label narrower than PBS population — TGA label requires prior stabilisation with acute treatment; PBAC assesses broader population of those who 'can be stabilised' without that prerequisite.